Kiniksa Pharmaceuticals (KNSA) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 3[1], 2 Phase 2[2].
Trial NCT07010159[4] evaluates KPL-387 in Pericarditis with a target enrollment of 165 participants.
KNSA has 13 Form 4 insider filings recorded at the SEC in the past 30 days[5].